Marsh
@zay111086718
Stocks $PRME $MGX $CRSP $TSLA $AMD $JOBY $HOOD not financial advice
🫡💡🧬
Now is the best time to buy $NTLA before investors start tripping over themselves to get in. The rest of the gene editing sector will likely follow, so it's smart to hold a diversified mix. Here's mine: $NTLA – Leading the pack in in-vivo treatments with strong clinical…
An incredibly accurate reading of the gene editing stocks. $MGX SRRONG BUY ALERT
My current view of the #CRISPR therapeutics stock market. $MGX $NTLA $PRME $SANA $EDIT $CRSP $BEAM
$TEM let’s ride
$TEM America’s New AI Healthcare Playbook Reads Like a Tempus AI Roadmap🚨 Now we know why Pelosi was loading up. She probably saw this six months ago. The July 2025 America’s AI Action Plan just went public, and it is the most bullish policy setup Tempus AI could have asked…
👀 $srpt
$srpt so a p value of 0.0016 that distribution of AAVrh47-related deaths random. More generally, most, if not all liver-related AAV deaths have been in patients that had liver issues to start with. If the FDA cant see that, I dont know.
New Analyst Recommendation $PRME 🧬📈 $10 - Outperform - BMO - 7/22 $6 - Outperform - Citizens - 7/21
$PRME big progress here.
Today in @CellCellPress we report the use of prime editing to correct several mutations that cause alternating hemiplegia of childhood (AHC), a rare and devastating neurodevelopmental disorder, in patient-derived cells and in two mouse models. drive.google.com/file/d/1ibC50t… 1/10
It will be painfully obvious when $MGX is far higher than this. IPO at $15 last year and will be back soon. A truly hidden gem trading at 1/4 its total cash.
One day, CRISPR companies will be completely decoupled from the biotech sector, the same way Tesla decoupled itself from legacy autos.
So what happened to David Liu automatic buys? David “Diamond Hands” Liu plz don’t dump them and crash $PRME on us @davidrliu
$MGX such an opportunity with 280m cash and a 70m market cap
Didn't buy $PRME at $1? Want another cheap yet high potential entry into the gene editing sector? Meet $MGX. Why $MGX (Metagenomi) could be sitting on one of biotech’s most undervalued data goldmines, and no one's paying attention (yet). 🧬 1/ A pet DNA dataset sold for over…
The 51m insider buy yesterday by a $CRSP board member is the 4th largest insider buy in the entire stock market in the last year. Something is coming $PRME $CRSP $BEAM
Yessir! Clean house bring in some fresh legs. The current executive team doesn’t have the juice for this. New ceo should bring in a new team.
If a high profile pharma savvy CSO steps in this could be very bullish, signaling a transition from research phase to commercial phase.
The future of healthcare
We are excited to share that we have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for our Tempus ECG-Low EF software, which uses AI to identify patients who may have a low left ventricular ejection fraction (LVEF). This is our second FDA approved…